8-K current report · filed Sep 22, 2026

Lexeo Therapeutics, Inc. (LXEO) 8-K Current Report: September 22, 2026

Item EX-99.1Item EX-99.2Item 1.01Item 8.01LXEO overview

Short answer

Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on September 22, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments.

Lexeo Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments
  • Up to $13.0M additional contingent consideration, including $1.0M cash and $12.0M milestone payments over 12 years
  • Milestones tied to Mantle product development and regulatory achievements, with no guaranteed payments
  • Key Mantle holders representing 76.1% of shares support approval, materially improving closing certainty
  • Closing requires stockholder approval and other customary conditions, with termination permitted after November 16, 2026

Item 8.01 · Other Events

  • Merger Agreement with Mantle Therapeutics and strategic collaborations mark a potentially transformative corporate development
  • Expected merger closing and contingent consideration remain subject to conditions and execution risks
  • CLARITY-FA study has 22 participants enrolled or imminently enrolling, advancing clinical development
  • September 22 conference call and webcast provide management’s transaction rationale and business update
  • Key risks include liquidity, clinical execution, regulatory approval, and uncertain translation from preclinical to clinical results

Item EX-99.1 · Exhibit EX-99.1

  • Mantle acquisition adds four FA programs across oral, protein-replacement, and ASO modalities for $8.3M upfront
  • Potential consideration reaches $21.3M, including $13.0M in success-based milestones
  • LX3010 showed approximately 6-point mFARS improvement and nine-fold frataxin increase across 11 patients at 16 weeks
  • Cash runway remains into 2028, including advancement of one acquired program; next FA IND targeted for 2027
  • SUNRISE-FA 2 remains the top priority, with topline data expected in 2H 2027

Item EX-99.2 · Exhibit EX-99.2

  • Mantle acquisition adds four FA programs spanning oral, protein-replacement and RNA approaches, broadening Lexeo beyond LX2006’s cardiac focus
  • Upfront consideration $8.3M, with success-based milestones up to $13M, payable in cash and equity
  • SUNRISE-FA 2 remains Lexeo’s highest operational and capital-allocation priority for LX2006 in FA cardiomyopathy
  • Cash runway guidance extends into 2028, including plans to advance one acquired program into clinical development
  • Program prioritization update expected early 2027, with an IND for the next FA development candidate planned in 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lexeo Therapeutics, Inc. 8-K filings

Get the next LXEO 8-K as it lands

Follow LXEO for push alerts, or ask the research agent what this filing means.